Aerie Pharmaceuticals Inc (NASDAQ:AERI) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 8,050,000 shares, a decline of 10.6% from the July 15th total of 9,000,000 shares. Based on an average trading volume of 879,200 shares, the days-to-cover ratio is currently 9.2 days. Approximately 18.4% of the company’s shares are sold short.
Several equities research analysts have recently issued reports on the company. SunTrust Banks lowered their price objective on Aerie Pharmaceuticals from $26.00 to $22.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Needham & Company LLC reduced their price objective on shares of Aerie Pharmaceuticals from $32.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday. Piper Sandler reduced their price target on Aerie Pharmaceuticals from $35.00 to $25.00 in a report on Friday. Mizuho boosted their price objective on Aerie Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a report on Friday. Finally, BidaskClub downgraded Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $31.50.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Endurance Wealth Management Inc. boosted its holdings in shares of Aerie Pharmaceuticals by 32.6% in the 1st quarter. Endurance Wealth Management Inc. now owns 3,050 shares of the company’s stock valued at $41,000 after buying an additional 750 shares in the last quarter. First Mercantile Trust Co. grew its holdings in Aerie Pharmaceuticals by 17.7% in the first quarter. First Mercantile Trust Co. now owns 8,124 shares of the company’s stock worth $110,000 after purchasing an additional 1,222 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Aerie Pharmaceuticals by 60.0% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,601 shares of the company’s stock worth $49,000 after purchasing an additional 1,351 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Aerie Pharmaceuticals by 39.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,030 shares of the company’s stock valued at $74,000 after purchasing an additional 1,429 shares during the last quarter. Finally, Swiss National Bank boosted its position in shares of Aerie Pharmaceuticals by 2.0% in the 1st quarter. Swiss National Bank now owns 85,200 shares of the company’s stock worth $1,150,000 after purchasing an additional 1,700 shares in the last quarter.
Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.79) by ($0.04). Aerie Pharmaceuticals had a negative net margin of 252.92% and a negative return on equity of 95.74%. Equities analysts expect that Aerie Pharmaceuticals will post -3.52 earnings per share for the current fiscal year.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Read More: Percentage Gainers
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.